Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.44 |
| ▸ | PPARA | Q07869 | 14/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503515 | 0.91 | FFAR1 (0.49) | PPARGPPARAUSP2SMN1; SMN2FFAR1 | |
| SCHEMBL6492166 | 0.80 | GAA (0.43) | SMN1; SMN2FAAH | |
| SCHEMBL6488150 | 0.79 | PLA2G2A (0.42) | FAAH | |
| SCHEMBL6498255 | 0.79 | FAAH (0.41) | PPARGPPARAPPARDFAAH | |
| SCHEMBL6489154 | 0.79 | ALDH1A1 (0.47) | PPARGSMN1; SMN2FAAH | |
| SCHEMBL6488639 | 0.78 | TARBP2 (0.47) | PPARGPPARAUSP2SMN1; SMN2PPARD | |
| SCHEMBL6496755 | 0.77 | PDE3B (0.44) | FAAH | |
| SCHEMBL6502360 | 0.77 | PABPC1 (0.39) | FAAH | |
| SCHEMBL6489292 | 0.76 | MCL1 (0.38) | FAAH | |
| SCHEMBL6501772 | 0.76 | PIK3C2B (0.47) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885PPARA 665/4885USP2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.